JPWO2019143950A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019143950A5 JPWO2019143950A5 JP2020539080A JP2020539080A JPWO2019143950A5 JP WO2019143950 A5 JPWO2019143950 A5 JP WO2019143950A5 JP 2020539080 A JP2020539080 A JP 2020539080A JP 2020539080 A JP2020539080 A JP 2020539080A JP WO2019143950 A5 JPWO2019143950 A5 JP WO2019143950A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- itr
- upstream
- downstream
- noi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862619468P | 2018-01-19 | 2018-01-19 | |
| US62/619,468 | 2018-01-19 | ||
| PCT/US2019/014211 WO2019143950A2 (en) | 2018-01-19 | 2019-01-18 | Methods and compositions for inhibition of innate immune response associated with aav transduction |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021511035A JP2021511035A (ja) | 2021-05-06 |
| JP2021511035A5 JP2021511035A5 (https=) | 2022-02-24 |
| JPWO2019143950A5 true JPWO2019143950A5 (https=) | 2022-02-24 |
| JP7504458B2 JP7504458B2 (ja) | 2024-06-24 |
Family
ID=67301987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539080A Active JP7504458B2 (ja) | 2018-01-19 | 2019-01-18 | Ａａｖ形質導入と関連付けられる自然免疫応答の阻害のための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200340013A1 (https=) |
| EP (1) | EP3740572A4 (https=) |
| JP (1) | JP7504458B2 (https=) |
| CN (1) | CN111918966B (https=) |
| AU (1) | AU2019210190B2 (https=) |
| CA (1) | CA3088538A1 (https=) |
| WO (1) | WO2019143950A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020270960B2 (en) | 2019-04-12 | 2026-01-29 | Ultragenyx Pharmaceutical Inc. | Engineered producer cell lines and methods of making and using the same |
| ES2827599B2 (es) * | 2019-11-21 | 2022-05-05 | Fundacion Para La Investigacion Biomedica Del Hospital Univ Nino Jesus | Celulas madre mesenquimales para ser usadas como vehiculos de agentes terapeuticos |
| US20220106609A1 (en) * | 2019-12-17 | 2022-04-07 | Nikegen, Llc | Paravoviral vectors and methods of making and use thereof |
| WO2021142130A1 (en) * | 2020-01-07 | 2021-07-15 | The University Of North Carolina At Chapel Hill | Synthetic adeno-associated virus inverted terminal repeats and methods of their use as promoters |
| US20250019668A1 (en) * | 2021-10-29 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Engineered cell lines for increased production of recombinant adeno-associated virus (raav) |
| WO2024123813A1 (en) * | 2022-12-05 | 2024-06-13 | The Trustees Of Columbia University In The City Of New York | Viral vectors for increasing the specificity of gene expression |
| CN117701638B (zh) * | 2023-12-18 | 2024-10-18 | 苏州新芽基因生物技术有限公司 | 一种抑制残留aav载体质粒和质粒骨架转录活性的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19959045A1 (de) * | 1999-12-07 | 2001-06-28 | Deutsches Krebsforsch | MCP-1 exprimierende AAV-Expressionsvektoren und deren therapeutische Verwendung |
| US20110206639A1 (en) * | 2004-04-15 | 2011-08-25 | Christie Vermeulen | Replication competent viruses capable of silencing virus inhibitory factor expression |
| US20110070241A1 (en) | 2009-06-30 | 2011-03-24 | Duke University | Methods for modulating immune responses to aav gene therapy vectors |
| WO2014145968A2 (en) * | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Rna interference functions as an antiviral immunity in mammals |
| EP3242945B1 (en) * | 2015-01-07 | 2021-09-01 | Universitat Autònoma de Barcelona | Single-vector gene construct comprising insulin and glucokinase genes |
| US20190000943A1 (en) * | 2015-08-13 | 2019-01-03 | Aavet Therapeutics, Llc | Aav6 vectors for immunotherapy |
-
2019
- 2019-01-18 US US16/963,023 patent/US20200340013A1/en active Pending
- 2019-01-18 CA CA3088538A patent/CA3088538A1/en active Pending
- 2019-01-18 AU AU2019210190A patent/AU2019210190B2/en active Active
- 2019-01-18 WO PCT/US2019/014211 patent/WO2019143950A2/en not_active Ceased
- 2019-01-18 JP JP2020539080A patent/JP7504458B2/ja active Active
- 2019-01-18 CN CN201980020389.7A patent/CN111918966B/zh active Active
- 2019-01-18 EP EP19741946.8A patent/EP3740572A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7651190B2 (ja) | 遺伝子操作ｒｎａを用いた内因性ａｄａｒによる標的化ｒｎａ編集 | |
| JP2021511035A5 (https=) | ||
| JP4763681B2 (ja) | ＲＮＡｉ作用媒介物の同時デリバリーのためのマルチプロモーター発現カセット | |
| US20250161485A1 (en) | Aav capsid variants and uses thereof | |
| CN101603042B (zh) | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 | |
| JP7706607B2 (ja) | 操作された産生細胞株ならびにそれを作製および使用する方法 | |
| US20110117608A1 (en) | Double-stranded nucleic acid | |
| CN101180394A (zh) | RNAi表达构建体 | |
| CN103635576A (zh) | 用于抑制乙型肝炎病毒的基因表达的组合物和方法 | |
| US20250297258A1 (en) | Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof | |
| CN105980551A (zh) | 腺相关病毒载体的高效生产 | |
| TR201908127T4 (tr) | Hbv tedavisi. | |
| US20240309368A1 (en) | Targeted rna editing by leveraging endogenous adar using engineered rnas | |
| US8008468B2 (en) | RNAi expression constructs with liver-specific enhancer/promoter | |
| US12071633B2 (en) | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer | |
| CN119654412A (zh) | 激活补体因子h表达的寡核苷酸调节剂 | |
| WO2025038430A1 (en) | Aav capsid variants and uses thereof | |
| WO2024226790A1 (en) | Aav capsid variants and uses thereof | |
| JPWO2019143950A5 (https=) | ||
| WO2023220719A2 (en) | Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting | |
| CN117545839A (zh) | 工程化CRISPR-Cas13f系统及其用途 | |
| CA3249545A1 (en) | OLIGONUCLEOTIDE MODULATORS ACTIVATING UTROPHIN EXPRESSION | |
| WO2024223931A1 (en) | Manufacturing and use of recombinant self-complementary aav vectors | |
| AU2023446284A1 (en) | Manufacturing and use of recombinant self-complementary aav vectors | |
| JPWO2020172720A5 (https=) |